Patients with current deep vein thrombosis or deep vein thrombosis within the past 6 months are not eligible
STEP I: Patients may have a history of current or previous deep vein thrombosis or pulmonary embolism but must be willing to take some form of anti-coagulation as prophylaxis if they are not currently on full-dose anticoagulation
Patients will be excluded if any of the following are present:\r\n* Evidence of active bleeding, intratumoral hemorrhage, or bleeding diathesis\r\n* History (within 6 months prior to study enrollment) of pulmonary embolism, deep vein thrombosis (DVT), or other venous thromboembolic event\r\n* History of hemoptysis within 6 weeks prior to study enrollment
History of pulmonary embolism within 6 months prior to the first dose of ALRN-6924 or untreated DVT (deep vein thrombosis)
Have had a prior thrombotic event (e.g., pulmonary embolism, deep vein thrombosis) or are currently receiving therapeutic or prophylactic doses of anticoagulants.
Participants with history of pulmonary embolism, deep vein thrombosis (DVT), or vascular access related thrombosis will be allowed on study provided they are receiving adequate anticoagulation at a stable dose at the time of study entry
Presence of deep vein thrombosis based on screening lower extremity Doppler ultrasonography.
History of blood clots, pulmonary embolism, or deep vein thrombosis unless on adequate anticoagulant therapy as determined by the treating investigator (subject must be on stable dose for 2 weeks).
History of deep vein thrombosis (DVT) or pulmonary embolism (PE) in the past 6 months
Patient must not have any thromboembolic event (deep vein thrombosis or pulmonary embolism) less than 3 weeks prior to enrollment
Deep vein thrombosis or pulmonary embolism =< 4 weeks before first dose of protocol-indicated treatment, unless adequately treated and stable.\r\n* Patients receiving therapeutic non-coumarin anticoagulation are eligible, provided they are on a stable dose (per investigator judgment) of anticoagulant.
A diagnosis of deep vein thromboses in the preceding four weeks of study enrollment.
Active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to Cycle 1/Day 1 (C1/D1) unless adequately treated and considered stable
Deep vein thrombosis (DVT) / pulmonary embolism (PE) in the past 6 months prior to randomization
Thrombotic events (pulmonary embolism; deep venous thrombosis) within 6 month prior to start of therapy
Have been treated for a deep vein thrombosis, pulmonary embolism, myocardial infarction, or ischemic stroke within the past 6 months (may be extended to 1 year if medically indicated per physician discretion).
Thromboembolic events and/or bleeding disorders ? 14 days (e.g., deep vein thrombosis (DVT) or pulmonary embolism (PE)) prior to the first dose of study drug
Patients unwilling to take deep vein thrombosis (DVT) prophylaxis.
History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of enrollment.
If prior history of deep vein thrombosis (DVT)/pulmonary embolism (PE), the patient needs to be on stable doses of anticoagulation with low molecular weight heparin or oral anticoagulant for at least two weeks
Active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to Cycle 1/Day 1 (C1/D1) unless adequately treated and considered stable
History or presence within the last 3 months of Deep Vein Thrombosis (DVT) or a pulmonary embolism (PE);- Uncontrolled leptomeningeal disease;
have a history of venous thromboembolism, including deep vein thrombosis, pulmonary embolism or retinal vein thrombosis, unless currently on anticoagulant therapy;
Subject has active or history of deep vein thrombosis (DVT)
History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of enrollment
Thromboembolic event (e.g., deep vein thrombosis [DVT] and pulmonary embolism [PE]) ? 4 weeks of C1D1.
Prior or concurrent deep vein thrombosis or pulmonary embolism
History of arterial thrombosis; patients with history of deep vein thrombosis (DVT) are eligible as long as they have received or are receiving appropriate anticoagulation therapy
Patients with documented deep venous thrombosis or pulmonary embolism within the past 3 months
History of deep vein thrombosis or pulmonary embolism within 6 month of anticipated starting of axitinib
Concurrent medical problems that preclude use of deep vein thrombosis (DVT) prophylaxis with lenalidomide treatment
Patients with active pulmonary embolism or deep vein thrombosis (diagnosed within 30 days of\r\nstudy enrollment)
Myocardial infarction, uncontrolled angina, congestive heart failure, or cerebrovascular accident within previous 6 months; subjects with a history of deep vein thrombosis or pulmonary embolism, at provider discretion
Subjects with a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 6 months of study treatment initiation
Any of the following in the previous 6 months: deep vein thrombosis or symptomatic pulmonary embolism
History of deep vein thrombosis or pulmonary embolism requiring systemic anticoagulation within 6 months before enrollment
significant cardiovascular disease within the last 3 months: including myocardial infarction, unstable angina, congestive heart failure, ongoing arrhythmias of Grade > 2 , thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism). Chronic stable atrial fibrillation on stable anticoagulant therapy is allowed.
History of deep venous thrombosis and pulmonary embolism (Phase 1b).
History of deep venous thrombosis (DVT) or pulmonary embolism (PE)
Recent venous thrombosis within 4 weeks prior to study registration; patients at high risk for thrombotic events due to inherited risk factors (i.e. factor V Leiden) or deep vein thrombosis (DVT)/pulmonary embolism (PE) in the past 12 months should be on secondary prophylaxis with anti-coagulant therapy (i.e. warfarin or low molecular weight heparin) prior to enrollment
Patients may have a history of current or previous deep vein thrombosis or pulmonary embolism but must be willing to initiate prophylaxis with low molecular weight heparin
Deep vein thrombosis or pulmonary embolism within 3 months of study entry
History of deep vein thrombosis and/or pulmonary embolism within 4 weeks of enrollment.
Active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to Cycle 1/Day 1 (C1/D1) unless adequately treated and considered stable
Active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to first administration of study drug unless adequately treated and considered by the Investigator to be stable.
Prior history of deep venous thrombosis or pulmonary embolism within 5 years prior to enrollment in the study and not currently on systemic anticoagulation
Deep vein thrombosis or pulmonary embolism =< 4 weeks before first dose of protocol-indicated treatment, unless adequately treated and stable
History of unprovoked deep vein thrombosis/pulmonary embolism (DVT/PE) in past twelve (12) months
History of vascular disease (e.g. deep vein thrombosis, stroke)
Acute deep vein thrombosis or clinically relevant pulmonary embolism, not stable for at least 4 weeks prior to first IMP administration.
Patients with any prior history of arterial thrombosis or symptomatic pulmonary embolism
Patients must not have a history of prior stroke, transient ischemic attack (TIA), pulmonary embolism, or untreated deep vein thrombosis\r\n* NOTE: Patients may be eligible if they have received at least 3 months of anticoagulation for a deep vein thrombosis
History of deep vein thrombosis or pulmonary embolism within 6 months of screening; patients who are currently taking anticoagulation therapy for a prior history (> 6 months from screening) of thrombosis may still be eligible
History of blood clots, pulmonary embolism, or deep vein thrombosis in previous 6 months unless controlled by anticoagulant treatment
Prior history of a major thrombotic event, such as pulmonary emboli, deep vein thrombosis or stroke, as assessed by the investigator, or history of an asparaginase associated serious hemorrhage or thrombus requiring anticoagulation therapy
Any history of a venous thromboembolic event (VTE), including deep vein thrombosis\n             (DVT) or pulmonary embolism (PE)
Patients may have a history of current or previous deep vein thrombosis or pulmonary embolism but are required to take some form of anti-coagulation as prophylaxis if they are not currently on full-dose anticoagulation
History of pulmonary embolism within 6 months prior to the first dose of ALRN-6924 or untreated DVT (deep vein thrombosis)
Has had within the past 6 months the occurrence of one or more of the following events: myocardial infarction, cerebrovascular accident, deep vein thrombosis, pulmonary embolism, hemorrhage (NCI CTCAE Grade 3 or 4), chronic liver disease (meeting criteria for Child-Pugh Class B or C), or organ transplantation.
History of thromboembolic events and/or bleeding disorders ? 14 days (e.g., deep vein thrombosis (DVT) or pulmonary embolism (PE)) prior to the first dose of study drug
Has a history of deep vein thrombosis or pulmonary embolism within 6 months of screening.
Absence of history of deep venous thrombosis/embolism, threatening thromboembolism or known thrombophilia; patients with a history of deep vein thrombosis(DVT)/pulmonary embolism (PE) or thrombophilia may participate if they are willing to be on full anticoagulation during the treatment if randomized to rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R2CHOP) arm A; full anticoagulation is defined as warfarin, factor X inhibitors, or low molecular weight heparin at therapeutic doses
Has had a deep venous thrombosis (DVT) or pulmonary embolism within the 3 months prior to study enrollment. NOTE: Subjects with a history of a DVT or pulmonary embolism >3 months prior to study enrollment who are on anticoagulation therapy with low molecular weight heparin are eligible for this study.
Patients with the following: \r\n* Bleeding diathesis or patients in whom prophylactic antithrombotic therapy is otherwise contraindicated \r\n* Patients with prior deep vein thrombosis (DVT), pulmonary embolism (PE), or arterial thromboembolism \r\n* Patients with ischemic stroke or transient ischemic attack (TIA)
Participants with prior history of thromboembolic disease (i.e. deep venous thrombosis [DVT] or pulmonary embolism [PE] within the last six months)
History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of enrollment.
Known, existing uncontrolled coagulopathy; patients who have had a venous thromboembolic event (e.g., pulmonary embolism or deep vein thrombosis) requiring anticoagulation are eligible IF: they are appropriately anticoagulated and have not had a grade 2 or greater bleeding episode in the 3 weeks before day 1
Has a history of blood clots, pulmonary embolism, or deep vein thrombosis unless controlled by anticoagulant treatment (patient must be on stable dose for 2 weeks).
Deep vein thrombosis (DVT)/pulmonary embolism (PE) in the past 6 months
History of blood clots, pulmonary embolism, or deep vein thrombosis unless controlled by anticoagulant treatment.
Have had a new pulmonary embolism, extremity deep venous thromboembolism, or portal vein thrombosis within 2 months of study enrollment (any thrombosis within 2 months of study enrollment must be approved by the protocol chair and/or medical monitor)
Patients with prior deep vein thrombosis (DVT) or pulmonary embolism (PE) currently on anticoagulation regimen will be permitted
History of thromboembolic events (e.g., deep vein thrombosis (DVT) or pulmonary embolism (PE)) ? 2 weeks before the first dose of study drug and/or clinical diffuse intravascular coagulation (DIC)
In past 6 months: deep vein thrombosis or pulmonary embolism
Evidence of deep vein thrombosis (DVT) or pulmonary embolism (PE) or other known thromboembolic event present during screening period.
Patients with active pulmonary embolism or deep vein thrombosis (diagnosed within 30 days of study enrollment)
Subjects with deep vein thrombosis (DVT) and Pulmonary embolism (PE) within 3 months prior to day 1 treatment
Venous thromboembolic events (e.g., deep vein thrombosis or pulmonary embolism) within 6 months of screening
Candidates may have a history of deep vein thrombosis, pulmonary embolism, and/or cerebrovascular accident, or require concomitant systemic anticoagulation, if otherwise deemed to be suitable for RP
Patient at high risk for deep vein thrombosis not willing to take DVT prophylaxis.
History of pulmonary embolism or deep vein thrombosis (DVT) within the past 6 months
History of pulmonary embolism or deep venous thrombosis within the past six months of the first dose of study treatment
The participant has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin or sudden cardiac arrest. Any participant with a history of venous thromboembolism (VTE) (for example, deep vein thrombosis [DVT] of the leg or arm and/or pulmonary embolism) will be excluded.
Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, arterial thrombosis) within 6 months prior to enrollment.
Deep vein thrombosis in the preceding 2 months.
Unstable pulmonary embolism, deep vein thrombosis, or other significant arterial/venous thromboembolic event =< 30 days before enrollment
Patients with active pulmonary embolism or deep vein thrombosis (diagnosed within 30 days of study enrollment)
No prior history of deep venous thrombosis or pulmonary embolism within 5 years prior to enrollment in the study
Pulmonary embolism, deep vein thrombosis, or other significant venous event =< 8 weeks before enrollment
Has had within the past 6 months the occurrence of one or more of the following events: myocardial infarction, cerebrovascular accident, deep vein thrombosis, pulmonary embolism, hemorrhage (CTC Grade 3 or 4), chronic liver disease (meeting criteria for Child-Pugh Class B or C), a second active malignancy (excluding basal cell carcinoma and cervical carcinoma in situ), organ transplantation.
History of deep venous thromboses or pulmonary embolism =< 365 days prior to registration
Have a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolic event during the 3 months prior to receiving study drugs.
Occurrence of deep vein thrombosis within 4 weeks, prior to study entry
Thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, arterial thrombosis) within 6 months of screening
Deep vein thrombosis diagnosed within 3 months
History within 3 months of deep vein thrombosis, pulmonary embolism, or stroke
Diagnosed active deep vein thrombosis (DVT) that has not been therapeutically anticoagulated
History of thromboembolic events and bleeding disorders ?3 months (e.g., (deep vein thrombosis) DVT or pulmonary embolism (PE))
Patients with a history of deep vein thrombosis or thromboembolism within < 6 months prior to starting study treatment
Prior or concurrent deep vein thrombosis or pulmonary embolism
No thrombotic event within 6 months (deep vein thrombosis, pulmonary embolism) of registration for protocol therapy.
History of deep vein thrombosis or pulmonary embolism.
Patients with a history of deep vein thrombosis or thromboembolism within < 6 months prior to starting study treatment
History of pulmonary embolism (PE), or untreated deep venous thrombosis (DVT) =< 180 days
Patients must not have a prior history of deep vein thrombosis (DVT) or pulmonary embolism in the past 5 years
Suspected or diagnosed deep vein thrombosis or painful foot neuropathy.
Active deep vein thrombosis in the treatment extremity
History of deep vein thrombosis (DVT) in the lymphedematous upper extremity
History of deep venous thrombosis or embolic event (eg, pulmonary embolism) within 6 months prior to randomization.
History of thrombosis, deep vein thrombosis, pulmonary emboli, or embolic stroke AND have not been stable on anticoagulants within the past 6 months; local central line thrombosis is allowed
Ongoing use or planned peri-operative use of anticoagulants (not including deep vein thrombosis [DVT] prophylaxis)
Known history of VTE prior to diagnosis (deep vein thrombosis [DVT] or pulmonary embolism PE) due to increased underlying risk of new event
History of blood clots (i.e. pulmonary embolism, deep vein thrombosis [DVTs])
History of deep vein thrombosis or pulmonary embolism within 4 weeks of first study dose
Patients with thrombosis within the splenic vein
Symptomatic deep vein thrombosis or pulmonary embolism within last 6 months
No thrombotic event within 6 months (deep vein thrombosis, pulmonary embolism) of starting IFN gamma
Patients who will require anticoagulant medications other than routine deep vein thrombosis (DVT) prophylaxis within 8 days postoperatively
History of deep vein thrombosis or pulmonary embolism.
Participants requires the use of warfarin (use in prophylactic doses [example, deep vein thrombosis prophylaxis]) is allowed.
